Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for gestational diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gestational diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on gestational diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Benefits and Risks of Oral Diabetes Agents Compared With Insulin in Women With GestationalDiabetes: A Systematic Review Little is known about the comparative risks and benefits of medical treatments for gestationaldiabetes mellitus (GDM). We conducted a systematic review of randomized controlled trials and observational studies of maternal and neonatal outcomes in women with GDM treated with oral diabetes agents compared with all types of insulin.We searched four electronic databases from (...) (n=1,229 participants) and five observational studies (n=831 participants). Data were abstracted on study characteristics, gestational age at treatment, medication dosage, and length of follow-up. Outcomes included glycemic control, infant birth weight, neonatal hypoglycemia, and congenital anomalies.Two trials compared insulin to glyburide; one trial compared insulin, glyburide, and acarbose; and one trial compared insulin to metformin. No significant differences were found in maternal glycemic
Screening for gestationaldiabetes Executive Summary IQWiG Reports – Commission No. S07-01 Screening for gestationaldiabetes 1 1 Translation of the executive summary of the final report “Screening auf Gestationsdiabetes” (Version 1.1; Status: 25.08.2009). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive summary of final report S07-01 Screening (...) for gestationaldiabetes Version 1.1 25.08.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Assessing the benefit and medical necessity of screening for gestationaldiabetes Contracting agency: Federal Joint Committee Commission awarded on: 10.05.2007 Internal Commission No.: S07-01 Publisher’s address: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel.: +49 221 35685-0 Fax: +49 221 35685-1 firstname.lastname@example.org
A multicenter, randomized trial of treatment for mild gestationaldiabetes. It is uncertain whether treatment of mild gestationaldiabetes mellitus improves pregnancy outcomes.Women who were in the 24th to 31st week of gestation and who met the criteria for mild gestationaldiabetes mellitus (i.e., an abnormal result on an oral glucose-tolerance test but a fasting glucose level below 95 mg per deciliter [5.3 mmol per liter]) were randomly assigned to usual prenatal care (control group (...) %). Treatment of gestationaldiabetes mellitus, as compared with usual care, was also associated with reduced rates of preeclampsia and gestational hypertension (combined rates for the two conditions, 8.6% vs. 13.6%; P=0.01).Although treatment of mild gestationaldiabetes mellitus did not significantly reduce the frequency of a composite outcome that included stillbirth or perinatal death and several neonatal complications, it did reduce the risks of fetal overgrowth, shoulder dystocia, cesarean delivery
A blood pressure before and during early pregnancy is associated with an increased risk of gestationaldiabetes mellitus While women with prior gestationaldiabetes mellitus (GDM) are more likely to display features of the metabolic syndrome, including hypertension, in the years after delivery, it is unclear whether these components are also present before pregnancy. We examined the relationship between blood pressure (BP) measured before and during early pregnancy (<20 weeks) and the risk (...) of GDM in a nested case-control study.Case (n = 381) and control (n = 942) subjects were selected from a cohort of women delivering between 1996 and 1998 and screened for GDM between 24 and 28 weeks' gestation. GDM was defined by the National Diabetes Data Group criteria. BP and covariates data were obtained by review of the medical records. Women were categorized according to BP levels recommended by the American Heart Association outside of pregnancy: <120/80 mmHg (normal), 120-139/80-89 mmHg
Gestational Weight Gain and GestationalDiabetes Mellitus: Perinatal Outcomes To examine the association between gestational weight gain and perinatal outcome in women with gestationaldiabetes mellitus (GDM).This is a retrospective cohort study of women with nonanomalous singleton pregnancies with GDM enrolled in the Sweet Success California Diabetes and Pregnancy Program between 2001 and 2004. Gestational weight gain, calculated from prepregnancy weight and weight at last prenatal Sweet (...) Success visit, was subgrouped into below, within, and above the Institute of Medicine (IOM) weight-gain guidelines. Perinatal outcomes were examined using chi2 test and multivariable regression analysis with 15-35-lb weight gain as the reference group.There were 31,074 women meeting study criteria. Compared with women with gestational weight gain within the IOM guidelines, women who gained above the guidelines had higher odds of having large for gestational age neonates (adjusted odds ratio [aOR] 1.72
Standards of medical care in diabetes. III. Detection and diagnosis of gestationaldiabetes mellitus (GDM). Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines
Screening for gestationaldiabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Update of 2003 U.S. Preventive Services Task Force (USPSTF) recommendation about screening for gestational diabetes.The USPSTF weighed the evidence on maternal and neonatal benefits (reduction in preeclampsia, mortality, brachial plexus injury, clavicular fractures, admission to the neonatal intensive care unit for serious illnesses) and harms (physical and psychological harms (...) ) of screening for gestationaldiabetes identified for their 2003 recommendation and the accompanying systematic review of articles published since the 2003 review for screening after 24 weeks' gestation. Additional searches were performed for evidence published from 1966 to 1999 on screening before 24 weeks.Current evidence is insufficient to assess the balance of benefits and harms of screening for gestationaldiabetes mellitus, either before or after 24 weeks' gestation. (I statement.).
Dietary advice in pregnancy for preventing gestationaldiabetes mellitus. Gestationaldiabetes mellitus (GDM) is a form of diabetes that occurs during pregnancy which can result in significant adverse outcomes for mother and child both in the short and long term. The potential for adverse outcomes, in addition to the increasing prevalence of gestationaldiabetes worldwide, demonstrates the need to assess strategies, such as dietary advice, that might prevent gestational diabetes.To assess (...) the effects of dietary advice in preventing gestationaldiabetes mellitus.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (January 2008) and reference lists of retrieved articles.Quasi-randomised and randomised studies of dietary intervention for preventing glucose intolerance in pregnancy.Two review authors independently conducted data extraction and quality assessment. We resolved disagreements through discussion or through a third author.Three trials (107 women) were included
High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestationaldiabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia The role of intrauterine hyperglycemia and future risk of type 2 diabetes in human offspring is debated. We studied glucose tolerance in adult offspring of women with either gestationaldiabetes mellitus (GDM) or type 1 diabetes, taking the impact of both intrauterine hyperglycemia and genetic predisposition to type 2 (...) diabetes into account.The glucose tolerance status following a 2-h 75-g oral glucose tolerance test (OGTT) was evaluated in 597 subjects, primarily Caucasians, aged 18-27 years. They were subdivided into four groups according to maternal glucose metabolism during pregnancy and genetic predisposition to type 2 diabetes: 1) offspring of women with diet-treated GDM (O-GDM), 2) offspring of genetically predisposed women with a normal OGTT (O-NoGDM), 3) offspring of women with type 1 diabetes (O-type 1
Metformin versus insulin for the treatment of gestationaldiabetes. Metformin is a logical treatment for women with gestationaldiabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking.We randomly assigned 751 women with gestationaldiabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia (...) outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin.In women with gestationaldiabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).Copyright 2008 Massachusetts Medical Society.
Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Nicholson W K, Wilson L M, Witkop C T, Baptiste-Roberts K, Bennett W L, Bolen S, Barone B B, Golden S H, Gary T L, Neale D M, Bass E B CRD summary This review assessed treatment, delivery (...) options and subsequent testing for type-2 diabetes for women with gestationaldiabetes. The authors concluded that there was insufficient evidence to recommend insulin alternatives or to formulate delivery guidelines and the 75-gm OGTT test should be retained for post-partum testing. This was a well-conducted review. The conclusions reflected the limited evidence accurately and are likely to be reliable. Authors' objectives Identified objectives were: to determine the efficacy and safety of oral
The role of exercise in preventing and treating gestationaldiabetes: a comprehensive review and recommendations for future research The role of exercise in preventing and treating gestationaldiabetes: a comprehensive review and recommendations for future research The role of exercise in preventing and treating gestationaldiabetes: a comprehensive review and recommendations for future research DiNallo J M, Downs D S CRD summary The authors concluded that exercise may have positive (...) and protective effects for the treatment and prevention of GDM (gestationaldiabetes mellitus). In view of poor reporting in the review, the small number of controlled studies, failure to assess or address heterogeneity between the studies and failure to systematically assess study quality, it is impossible to determine the reliability of the conclusions. Authors' objectives To assess the effects of exercise for treating, preventing or delaying GDM. Searching PsycLit, MEDLINE, Dissertation Abstracts Online
Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Hillier T A, Vesco K K, Whitlock E P, Pettitt D J, Pedula K L, Beil T L CRD summary The authors of this well-conducted review concluded that the limited evidence about early (<24 weeks) gestationaldiabetes mellitus (GDM) indicates a need for more research. The conclusion, which was based on one recent good-quality study in which screening identified women (...) with mild GDM after 24 weeks' gestation and improved maternal and neonatal outcomes, is likely to be reliable. Authors' objectives To evaluate the benefits and harms of screening for gestationaldiabetes mellitus (GDM). Searching MEDLINE, the Cochrane CENTRAL Register, the Cochrane Database of Systematic Reviews, DARE, HTA and the National Institute for Health and Clinical Excellence were searched from 2000 to September 2006l the search terms were reported. In addition, the reference lists from
Screening for gestationaldiabetes Screening for gestationaldiabetes Screening for gestationaldiabetes Liufu V, Mundy L, Hiller JE Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Liufu V, Mundy L, Hiller JE. Screening for gestationaldiabetes. Adelaide: Adelaide Health Technology Assessment (AHTA). Prioritising Summary. Volume 21. 2008 (...) Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes, Gestationals; Mass Screening; Pregnancy Language Published English Country of organisation Australia English summary An English language summary is available. Address for correspondence Adelaide Health Technology Assessment, University of Adelaide, Discipline of Public Health, School of Population Health and Clinical Practice, Mail Drop DX650545, SA 5005 Adelaide Australia Email: email@example.com
Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Screening for gestationaldiabetes mellitus Hillier T, Vesco K, Whitlock E, Pettitt D, Pedula K, Beil T Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hillier T, Vesco K, Whitlock E, Pettitt D, Pedula K, Beil T. Screening for gestationaldiabetes (...) be to detect previously unrecognized diabetes (GDM is defined as onset or first recognition of diabetes during pregnancy). Therefore, more research is needed before this question can be evaluated. A recent good-quality randomized controlled trial reported that treatment of screen-detected women with mild GDM diagnosed after 24 weeks gestation reduces both maternal and composite neonatal health outcomes, without apparent harm—as reported in this RCT and in several other observational studies. Project page
Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes Nicholson WK, Wilson LM, Witkop CT, Baptiste-Roberts K, Bennett WL, Bolen S, Barone BB, Golden SH, Gary TL, Neale DM, Bass EB Citation Nicholson WK, Wilson LM, Witkop CT, Baptiste-Roberts K (...) , Bennett WL, Bolen S, Barone BB, Golden SH, Gary TL, Neale DM, Bass EB. Therapeutic management, delivery, and postpartum risk assessment and screening in gestationaldiabetes. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 162. 2008 Authors' objectives
We focused on four questions: (1) What are the risks and benefits of an oral diabetes agent (i.e., glyburide), as compared to all types of insulin, for gestationaldiabetes? (2) What
Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestationaldiabetes mellitus AIM: The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus therapy for subjects with gestationaldiabetes mellitus (GDM). METHODS: In a randomized, parallel-group, open-labelled trial, 27 women with GDM (age 30.7 +/- 6.3 years, HbA(1c